Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : iPSC-based cell therapy
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Columbus Venture Partners
Deal Size : $17.2 million
Deal Type : Financing
Tolerance Bio Launches with $17.2M to Advance Thymus-Based Immune Therapies
Details : The proceeds from the financing will be used to advance thymus-based therapies for immune-mediated diseases.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 15, 2024
Lead Product(s) : iPSC-based cell therapy
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Columbus Venture Partners
Deal Size : $17.2 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?